Nanobiotix Shares Drop Nearly 3% Yet Maintain an Annual Gain of 692%
French biotech company Nanobiotix pauses this Wednesday after several sessions of strong gains. The stock is among the most notable declines in the SBF 120, while the Paris market hovers around equilibrium. The downturn comes amid profit-taking, with the stock showing an extraordinary annual performance.
A Decline that Interrupts the Uptrend and Weakens the Resistance at €36.20
Nanobiotix's stock falls by 2.82% to €35.18, below a previously breached resistance at €36.20. The stock ranks at the bottom of the SBF 120 index, among the steepest declines, while Worldline and Kering lead the gains. Today's movement contrasts with the rebound of more than 5% last Friday, which had pushed the stock to near its highs. Despite this setback, the one-year performance remains impressive at nearly 692%, with a three-month gain still over 26%.
The Stock Remains Above Its Moving Averages Despite Profit-Taking
In terms of indicators, the stock maintains a comfortable cushion above its moving averages: more than 8% above the MM20 at €32.57, and nearly 42.5% above the MM200 at €24.69. The RSI at 62 indicates a still robust momentum, without a marked overbought signal. The technical support is at €28.28, providing a margin of about 20% below the current price.
During the Q1 2026 report (June 2, 2026), the company highlighted the progress of clinical studies on JNJ-1900 (NBTXR3), a central catalyst in the case. The next medium-term milestone remains the stock's ability to regain its footing above the €36.20 resistance level.
